Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review

Peripheral T‐cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T‐cells, and constitute less than 15% of all non‐Hodgkin's lymphomas (NHLs) in adults. The current WHO classification recognizes nine distinct clinicopathologic peripheral T...

Full description

Saved in:

Bibliographic Details
Published in:	Hematological oncology Vol. 26; no. 1; pp. 8 - 20
Main Authors:	Rodriguez-Abreu, Delvys, Filho, Volmar Belisario, Zucca, Emanuele
Format:	Journal Article
Language:	English
Published:	Chichester, UK John Wiley & Sons, Ltd 01-03-2008
Subjects:	Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Gene Expression Profiling Hematopoietic Stem Cell Transplantation Humans Immunophenotyping Immunotoxins - therapeutic use Lymphoma, T-Cell, Peripheral - genetics Lymphoma, T-Cell, Peripheral - immunology Lymphoma, T-Cell, Peripheral - therapy non-Hodgkin lymphoma peripheral T-cell lymphoma peripheral T‐cell lymphoma, unspecified Prognosis Proteasome Inhibitors unspecified
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Peripheral T‐cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T‐cells, and constitute less than 15% of all non‐Hodgkin's lymphomas (NHLs) in adults. The current WHO classification recognizes nine distinct clinicopathologic peripheral T‐cell NHLs, being the ‘unspecified variant’ (PTCL‐U) the most common subtype. These neoplasms often present in advanced stage at diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. The rarity of these tumours requires additional studies to better understand their biology and search for new therapies which may hopefully improve the dismal outcome of most patients. This review aims to describe the pathobiological aspects as well the clinical characteristics and current therapeutic strategies of the PTCLs, with special attention to the group of PTCL‐U Copyright © 2007 John Wiley & Sons, Ltd.
AbstractList	Peripheral T‐cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T‐cells, and constitute less than 15% of all non‐Hodgkin's lymphomas (NHLs) in adults. The current WHO classification recognizes nine distinct clinicopathologic peripheral T‐cell NHLs, being the ‘unspecified variant’ (PTCL‐U) the most common subtype. These neoplasms often present in advanced stage at diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. The rarity of these tumours requires additional studies to better understand their biology and search for new therapies which may hopefully improve the dismal outcome of most patients. This review aims to describe the pathobiological aspects as well the clinical characteristics and current therapeutic strategies of the PTCLs, with special attention to the group of PTCL‐U Copyright © 2007 John Wiley & Sons, Ltd. Peripheral T-cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T-cells, and constitute less than 15% of all non-Hodgkin's lymphomas (NHLs) in adults. The current WHO classification recognizes nine distinct clinicopathologic peripheral T-cell NHLs, being the 'unspecified variant' (PTCL-U) the most common subtype. These neoplasms often present in advanced stage at diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. The rarity of these tumours requires additional studies to better understand their biology and search for new therapies which may hopefully improve the dismal outcome of most patients. This review aims to describe the pathobiological aspects as well the clinical characteristics and current therapeutic strategies of the PTCLs, with special attention to the group of PTCL-U.
Author	Filho, Volmar Belisario Rodriguez-Abreu, Delvys Zucca, Emanuele
Author_xml	– sequence: 1 givenname: Delvys surname: Rodriguez-Abreu fullname: Rodriguez-Abreu, Delvys organization: IOSI, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland – sequence: 2 givenname: Volmar Belisario surname: Filho fullname: Filho, Volmar Belisario organization: IOSI, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland – sequence: 3 givenname: Emanuele surname: Zucca fullname: Zucca, Emanuele email: ielsg@ticino.com organization: IOSI, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/18050364$$D View this record in MEDLINE/PubMed
BookMark	eNp10EtPAjEUBeDGYOSh8R-Y7tTo4G3LdGbcGVRQCRiDYdkM5TaMzistiPx7xwzBlauzOF_O4rRJIy9yJOSUQZcB8JtlkXdDIQ9Ii0EUeQxk1CAt4EHoARe8SdrOfQBUHYRHpMlC8EHIXotMXtEm5RJtnNKppzFNabrNymWRxe6arnNXok5Mggt6UViaFytarCq9SRzSfXd5S2Nq8SvBzTE5NHHq8GSXHfL--DDtD73RZPDUvxt5WvhCekIwrfV8LsFw4zMJPEYThiIOIWABl0ZiJHkv5AsZRGBMUNVSaq51ZARCT3TIeb2rbeGcRaNKm2Sx3SoG6vcSVV2iqksqeVbLcj3PcPHndh9U4KoGmyTF7X87ajgZ13NerRO3wu-9ju2nkoEIfDUbD9SzP32bvbB7NRM_xyF6uQ
CitedBy_id	crossref_primary_10_1007_s11604_018_0780_x crossref_primary_10_1111_j_1600_0609_2011_01597_x crossref_primary_10_1016_j_jhsa_2014_01_033 crossref_primary_10_1080_13696998_2022_2041320 crossref_primary_10_1093_annonc_mdq359 crossref_primary_10_2478_prolas_2020_0023 crossref_primary_10_1093_ndt_gfq231 crossref_primary_10_1155_2015_429068 crossref_primary_10_3960_jslrt_51_29 crossref_primary_10_2460_javma_249_12_1375 crossref_primary_10_1007_s13671_017_0173_x crossref_primary_10_1016_j_bbmt_2008_11_010 crossref_primary_10_1038_bcj_2012_8 crossref_primary_10_1200_JCO_2012_41_6644 crossref_primary_10_1517_17425255_2011_595404 crossref_primary_10_1007_s11812_009_0062_8 crossref_primary_10_1002_hon_832 crossref_primary_10_1016_j_clml_2020_07_011 crossref_primary_10_3109_08880018_2015_1074325 crossref_primary_10_1007_s12185_013_1383_z crossref_primary_10_1097_MPH_0000000000000368 crossref_primary_10_1007_s00277_016_2597_y crossref_primary_10_2165_11635690_000000000_00000 crossref_primary_10_1080_01658107_2020_1779317 crossref_primary_10_1097_LBR_0b013e3181da2a60 crossref_primary_10_4103_CRST_CRST_85_19 crossref_primary_10_1186_1752_1947_3_83 crossref_primary_10_18553_jmcp_2023_29_3_314 crossref_primary_10_1177_1430_15810 crossref_primary_10_1182_blood_2009_05_220111 crossref_primary_10_1038_leu_2012_120 crossref_primary_10_1111_j_1346_8138_2010_00914_x crossref_primary_10_1007_s12254_009_0145_3 crossref_primary_10_1007_s12105_008_0086_x crossref_primary_10_1111_j_1365_3164_2012_01106_x crossref_primary_10_1097_MOH_0b013e3283623c07
Cites_doi	10.1007/978-3-642-97187-7 10.1182/blood-2003-10-3389 10.1182/blood.V104.11.2486.2486 10.1046/j.1365-2141.2003.04203.x 10.1182/blood.V96.2.685.014k26_685_690 10.1007/s00277-002-0556-2 10.1038/modpathol.3800625 10.1182/blood.V89.11.3909 10.1200/JCO.2001.19.2.376 10.1182/blood.V80.7.1804.1804 10.1016/S0046-8177(86)80128-9 10.1182/blood-2004-03-1206 10.1182/blood.V72.2.436.436 10.1002/1097-0142(19930401)71:7<2335::AID-CNCR2820710727>3.0.CO;2-D 10.1182/blood.V84.5.1361.1361 10.1002/ijc.2910420103 10.1038/sj.thj.6200359 10.1038/nri1714 10.1093/annonc/mdf033 10.1182/blood.V87.3.1045.bloodjournal8731045 10.1093/oxfordjournals.annonc.a057673 10.1111/j.1365-2141.2005.05755.x 10.4049/jimmunol.173.10.6169 10.1016/j.coi.2006.03.017 10.1182/blood.V106.11.4764.4764 10.1136/jcp.40.9.995 10.1200/JCO.2005.03.6327 10.1038/sj.jid.5700122 10.1016/S0959-8049(01)00344-6 10.1159/000227554 10.1182/blood.V80.3.587.587 10.1182/blood.V83.2.505.505 10.1200/JCO.1999.17.12.3835 10.1038/sj.leu.2403960 10.1016/S0165-4608(99)00151-X 10.1093/annonc/mdh263 10.1097/00000478-198805000-00002 10.1182/blood-2006-04-017632 10.1002/path.2046 10.1182/blood-2002-05-1352 10.1172/JCI119728 10.1182/blood.V93.11.3913 10.1200/JCO.1994.12.12.2588 10.1084/jem.192.11.1545 10.3816/CLM.2000.s.010 10.1023/A:1008384506227 10.1002/cncr.11899 10.1016/S0360-3016(02)02916-4 10.1182/blood.V83.6.1612.1612 10.1158/1078-0432.CCR-04-0371 10.1111/j.1365-2141.2006.06457.x 10.1038/sj.onc.1209178 10.1182/blood-2003-09-3068 10.1182/blood.V96.12.3681 10.1016/j.coi.2005.09.002 10.1002/hon.781 10.1111/j.0902-4441.2005.00575.x 10.1097/00000478-200604000-00009 10.1056/NEJM200007133430207 10.1093/annonc/mdh409 10.1182/blood-2004-06-2181 10.3816/CLM.2003.n.027 10.1200/JCO.2001.19.17.3766 10.1023/A:1008200307625 10.1200/JCO.1991.9.8.1426 10.1056/NEJM200007063430107 10.1200/JCO.2000.18.13.2603 10.1002/cncr.21449 10.1111/j.1749-6632.2001.tb03724.x 10.1089/aid.1994.10.1557 10.1093/annonc/mdh392 10.1080/10428190210190 10.1016/0165-4608(94)90040-X 10.5507/bp.2007.019 10.1200/JCO.2004.12.050 10.1200/JCO.1997.15.6.2296 10.1182/blood.V104.11.2636.2636 10.1200/JCO.1989.7.6.725 10.1182/blood-2003-02-0542 10.1038/nature04753 10.3109/10428199609045720 10.1016/S0140-6736(87)92359-2 10.1158/1078-0432.CCR-04-0269 10.1182/blood-2003-09-3080 10.1182/blood.V104.11.2640.2640 10.1385/MO:22:2:191 10.1038/sj.leu.2403936 10.1046/j.1365-2141.2001.02743.x 10.1182/blood.V104.11.2637.2637 10.1111/j.1349-7006.2005.00080.x 10.1111/j.1365-2141.2005.05478.x 10.2174/138945006778559139 10.1182/blood.V89.12.4514 10.1038/labinvest.3700145 10.1182/blood.V98.9.2865 10.1016/S0002-9440(10)63742-X 10.1038/sj.onc.1210368 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8 10.1080/1042819021000030054 10.1023/A:1008418727472 10.1093/annonc/mdh143 10.1182/blood.V87.4.1207.bloodjournal8741207 10.1080/10428190600563821 10.1111/j.1365-2141.2004.04999.x 10.1002/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO;2-B 10.1038/sj.bmt.1705265 10.1016/j.leukres.2004.04.016 10.1200/JCO.1997.15.3.1131 10.1002/hon.786 10.1002/ajh.2830460304 10.1056/NEJM199304083281404
ContentType	Journal Article
Copyright	Copyright © 2007 John Wiley & Sons, Ltd.
Copyright_xml	– notice: Copyright © 2007 John Wiley & Sons, Ltd.
DBID	BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION
DOI	10.1002/hon.836
DatabaseName	Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef
DatabaseTitleList	CrossRef MEDLINE
Database_xml	– sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1099-1069
EndPage	20
ExternalDocumentID	10_1002_hon_836 18050364 HON836 ark_67375_WNG_J5TRWK1D_W
Genre	reviewArticle Journal Article Review
GroupedDBID	--- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GLUZI GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 TEORI UB1 UDS V2E V8K W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XV2 ZGI ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION
ID	FETCH-LOGICAL-c3536-331cccbb60f2f51602aef883a8071726f6e962482d6790ff7aef66c2cc9f3e043
IEDL.DBID	33P
ISSN	0278-0232
IngestDate	Fri Nov 22 00:34:06 EST 2024 Sat Sep 28 07:55:03 EDT 2024 Sat Aug 24 00:53:02 EDT 2024 Wed Oct 30 09:55:18 EDT 2024
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3536-331cccbb60f2f51602aef883a8071726f6e962482d6790ff7aef66c2cc9f3e043
Notes	istex:59CE2339FBC4091D0F74C46758FE0E749EF19CBC ark:/67375/WNG-J5TRWK1D-W ArticleID:HON836
PMID	18050364
PageCount	13
ParticipantIDs	crossref_primary_10_1002_hon_836 pubmed_primary_18050364 wiley_primary_10_1002_hon_836_HON836 istex_primary_ark_67375_WNG_J5TRWK1D_W
PublicationCentury	2000
PublicationDate	2008-03-01
PublicationDateYYYYMMDD	2008-03-01
PublicationDate_xml	– month: 03 year: 2008 text: 2008-03-01 day: 01
PublicationDecade	2000
PublicationPlace	Chichester, UK
PublicationPlace_xml	– name: Chichester, UK – name: England
PublicationTitle	Hematological oncology
PublicationTitleAlternate	Hematol. Oncol
PublicationYear	2008
Publisher	John Wiley & Sons, Ltd
Publisher_xml	– name: John Wiley & Sons, Ltd
References	Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18(3): 349-356. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103(12): 4636-4643. Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 1994; 46(3): 179-183. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120(6): 978-985. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93(8): 2697-2706. Schlegelberger B, Himmler A, Godde E, Grote W, Feller AC, Lennert K. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas. Blood 1994; 83(2): 505-511. Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996; 24(1-2): 121-129. Schlegelberger B, Himmler A, Bartles H, Kuse R, Sterry W, Grote W. Recurrent chromosome abnormalities in peripheral T-cell lymphomas. Cancer Genet Cytogenet 1994; 78(1): 15-22. Ansell S, Byrd J, Horwitz S, et al. Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma. Blood 2004; 104: (abs. #2636) 721a. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T-cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5(11): 853-865. Hagberg H, Pettersson M, Bjerner T, Enblad G. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 2005; 22: 2191-2194. Strupp C, Aivado M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002; 43(1): 133-137. Bluestone JA, Tang Q. How do CD4+ CD25+ regulatory T-cells control autoimmunity? Curr Opin Immunol 2005; 17(6): 638-642. Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88(12): 1372-1377. Armitage JO, Coiffier B. Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol 2000; 11(3): 359-361. Suchi T, Lennert K, Tu LY, et al. Histopathology and immunohistochemistry of peripheral T-cell lymphomas: a proposal for their classification. J Clin Pathol 1987; 40(9): 995-1015. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12(12): 2588-2593. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 82920-82924. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-airlie house, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835-3849. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98(9): 2865-2868. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18(13): 2603-2606. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328(14): 1002-1006. Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7(6): 725-731. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54(1): 182-190. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006; 25(10): 1560-1570. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113(1): 185-187. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104(11): 2437-2441. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87(4): 1207-1210. Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004; 15(7): 1091-1096. Lepretre S, Buchonnet G, Stamatoullas A, et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000; 117(1): 71-79. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004; 15(10): 1447-1449. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136(3): 439-447. Di Venuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma 2003; 4(3): 176-178. Weidmann E, Hess G, Krause S, et al. Combination chemoimmunotherapy using Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (campath-FCD) is an effective first-line regimen in peripheral T-cell lymphomas. Blood 2004; 104: abstract 2640. Estes JD, Thacker TC, Hampton DL, et al. Follicular dendritic cell regulation of CXCR4-mediated germinal center CD4 T-cell migration. J Immunol 2004; 173(10): 6169-6178. Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38(1): 75-81. Monfardini S, Sorio R, Cavalli F, et al. Pentostatin (2′-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 1996; 53(2): 163-168. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80(7): 1804-1812. Lay JD, Tsao CJ, Chen JY, Kadin ME, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T-cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100(8): 1969-1979. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47(6): 998-1005. Piccaluga PP, Agostinelli C, Zupo S, et al. Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals the existance of two subgroups related to different-cellular counterparts. Ann Oncol 2005; 16(Suppl. 5): v74 (abs. #125). Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10(16): 5494-5500. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19(2): 376-388. Levine PH, Blattner WA, Clark J, et al. Geographic distribution of HTLV-I and identification of a new high-risk population. Int J Cancer 1988; 42(1): 7-712. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 26(25): 3699-3703. Reimer P, Schertlin T, Rudiger T, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5(4): 304-311. Geissinger E, Bonzheim I, Krenacs L, et al. Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations. J Pathol 2006; 210(2): 172-180. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15(10): 1467-1475. Vidal AU, Gessain A, Yoshida M, et al. Molecular epidemiology of HTLV type I in Japan: evidence for two distinct ancestral lineages with a particular geographical distribution. AIDS Res Hum Retroviruses 1994; 10(11): 1557-1566. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89(11): 3909-3918. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's l 2004; 22 2004; 164 2006; 30 2004; 28 2002; 13 2006; 37 2004; 5 1988; 72 2006; 210 1997; 8 2001; 941 2000; 18 1987; 40 2006; 24 2004; 173 2005; 104 2000; 11 2005; 105 2000; 96 2006; 25 2005; 106 1994; 78 1998; 92 2005; 1006 2006; 441 2003; 44 1989; 63 2000; 117 1989; 7 1986; 17 1988; 12 2002; 81 1992 1994; 83 1994; 84 1987; 59 2000; 192 1990; 1 2005; 19 2006; 108 2007; 151 2006; 47 2005; 5 2005; 129 1994; 12 2005; 96 2005; 6 1999; 111 2000; 343 2005; 16 2005; 17 2003; 102 1996; 87 1994; 10 1998; 9 2003; 22 1987; 2 2004; 126 1997; 82 1993; 328 2005; 131 2006; 76 2002; 54 1997; 89 2000; 1 2005; 22 2007; 136 2001 1993; 71 1997; 15 1999; 17 1997; 100 2002; 43 2001; 19 2003; 4 1988; 42 1999; 93 1996; 24 2006; 126 2007; 26 2003; 120 2003; 88 2001; 98 2002; 38 2004; 100 1992; 80 2004; 104 2004; 84 2004; 103 2006; 17 2006; 7 2006; 18 2006; 19 1994; 46 2006 2004 2002 1991; 9 1996; 53 2004; 10 2001; 113 2004; 15 1985; 118 e_1_2_1_111_2 e_1_2_1_81_2 e_1_2_1_89_2 e_1_2_1_20_2 e_1_2_1_43_2 e_1_2_1_62_2 e_1_2_1_85_2 e_1_2_1_24_2 e_1_2_1_47_2 Coiffier B (e_1_2_1_64_2) 1990; 1 e_1_2_1_28_2 e_1_2_1_107_2 e_1_2_1_92_2 e_1_2_1_103_2 Schlegelberger B (e_1_2_1_40_2) 1994; 83 Ralfkiaer E (e_1_2_1_49_2) 2001 Gisselbrecht C (e_1_2_1_63_2) 1998; 92 e_1_2_1_126_2 d'Amore F (e_1_2_1_76_2) 1996; 87 e_1_2_1_54_2 e_1_2_1_4_2 e_1_2_1_77_2 e_1_2_1_50_2 e_1_2_1_96_2 e_1_2_1_31_2 e_1_2_1_16_2 Jaffe ES (e_1_2_1_2_2) 2001 Wolke C (e_1_2_1_26_2) 2006; 17 e_1_2_1_35_2 Rodriguez J (e_1_2_1_122_2) 2003; 88 e_1_2_1_58_2 e_1_2_1_8_2 e_1_2_1_39_2 Ansell S (e_1_2_1_102_2) 2004; 104 e_1_2_1_110_2 de Bruin PC (e_1_2_1_12_2) 1994; 83 e_1_2_1_114_2 e_1_2_1_67_2 e_1_2_1_44_2 e_1_2_1_21_2 Weiss LM (e_1_2_1_53_2) 1985; 118 d'Amore F (e_1_2_1_99_2) 2005; 106 e_1_2_1_25_2 e_1_2_1_29_2 Zinzani PL (e_1_2_1_94_2) 2000; 18 Armitage JO (e_1_2_1_17_2) 2004 Harris NL (e_1_2_1_68_2) 1994; 84 e_1_2_1_70_2 e_1_2_1_121_2 e_1_2_1_106_2 e_1_2_1_125_2 e_1_2_1_7_2 Cheng AL (e_1_2_1_72_2) 1989; 7 e_1_2_1_78_2 e_1_2_1_3_2 Saven A (e_1_2_1_129_2) 1992; 80 e_1_2_1_32_2 e_1_2_1_51_2 e_1_2_1_74_2 e_1_2_1_93_2 e_1_2_1_13_2 e_1_2_1_36_2 Armitage JO (e_1_2_1_55_2) 2002 e_1_2_1_59_2 Zinzani PL (e_1_2_1_115_2) 2005; 106 e_1_2_1_113_2 e_1_2_1_117_2 e_1_2_1_41_2 Rodriguez J (e_1_2_1_118_2) 2001; 19 Czuczman M (e_1_2_1_95_2) 2004; 104 e_1_2_1_22_2 e_1_2_1_45_2 e_1_2_1_60_2 e_1_2_1_83_2 e_1_2_1_120_2 Jones D (e_1_2_1_33_2) 2000; 96 Forero‐Torres A (e_1_2_1_101_2) 2004; 104 e_1_2_1_109_2 e_1_2_1_124_2 e_1_2_1_90_2 e_1_2_1_128_2 Weidmann E (e_1_2_1_97_2) 2004; 104 e_1_2_1_105_2 Delmer A (e_1_2_1_87_2) 2003; 22 e_1_2_1_75_2 e_1_2_1_56_2 e_1_2_1_71_2 e_1_2_1_131_2 e_1_2_1_10_2 e_1_2_1_52_2 e_1_2_1_14_2 e_1_2_1_79_2 e_1_2_1_18_2 e_1_2_1_80_2 e_1_2_1_112_2 e_1_2_1_116_2 e_1_2_1_65_2 Kwak LW (e_1_2_1_73_2) 1991; 9 e_1_2_1_88_2 Bouabdallah R (e_1_2_1_86_2) 2005; 16 e_1_2_1_23_2 e_1_2_1_61_2 e_1_2_1_42_2 e_1_2_1_84_2 Jaffe ES (e_1_2_1_37_2) 1999; 111 e_1_2_1_27_2 e_1_2_1_46_2 Dang N (e_1_2_1_98_2) 2005; 6 Vose JM (e_1_2_1_6_2) 2005; 1006 e_1_2_1_108_2 Anagnostopoulos I (e_1_2_1_11_2) 1992; 80 Melnyk A (e_1_2_1_66_2) 1997; 89 Cheung MM (e_1_2_1_82_2) 2002; 13 e_1_2_1_91_2 e_1_2_1_100_2 e_1_2_1_123_2 e_1_2_1_104_2 e_1_2_1_127_2 Falini B (e_1_2_1_69_2) 1999; 93 e_1_2_1_30_2 e_1_2_1_5_2 e_1_2_1_34_2 e_1_2_1_130_2 e_1_2_1_15_2 e_1_2_1_38_2 Piccaluga PP (e_1_2_1_48_2) 2005; 16 Zaja F (e_1_2_1_119_2) 1997; 82 e_1_2_1_19_2 e_1_2_1_57_2 e_1_2_1_9_2
References_xml	– volume: 164 start-page: 1837 issue: 5 year: 2004 end-page: 1848 article-title: Genomic profiling of peripheral T‐cell lymphoma, unspecified, and anaplastic large T‐cell lymphoma delineates novel recurrent chromosomal alterations publication-title: Am J Pathol – start-page: 227 year: 2001 end-page: 229 – volume: 19 start-page: 1101 issue: 8 year: 2006 end-page: 1107 article-title: Expression of CXCL13, a chemokine highly upregulated in germinal center T‐helper cells, distinguishes angioimmunoblastic T‐cell lymphoma from peripheral T‐cell lymphoma, unspecified publication-title: Mod Pathol – volume: 441 start-page: 235 issue: 7090 year: 2006 end-page: 238 article-title: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T‐cells publication-title: Nature – volume: 4 start-page: 176 issue: 3 year: 2003 end-page: 178 article-title: Denileukin diftitox and hyper‐CVAD in the treatment of human T‐cell lymphotropic virus 1‐associated acute T‐cell leukemia/lymphoma publication-title: Clin Lymphoma – volume: 22 start-page: 2191 year: 2005 end-page: 2194 article-title: Treatment of a patient with a nodal peripheral T‐cell lymphoma (angioimmunoblastic T‐Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax‐CD4) publication-title: Med Oncol – volume: 22 start-page: 2172 issue: 11 year: 2004 end-page: 2176 article-title: Graft‐versus‐lymphoma effect in relapsed peripheral T‐cell non‐Hodgkin's lymphomas after reduced‐intensity conditioning followed by allogeneic transplantation of hematopoietic cells publication-title: J Clin Oncol – volume: 16 start-page: v131 issue: Suppl. 5 year: 2005 article-title: ESHAP chemotherapy regimen and 13‐cis‐retinoic acid in elderly patients with untreated poor‐prognosis peripheral T‐cell lymphoma: a GELA phase II trial of feasability and efficacy publication-title: Annals of Oncology – volume: 30 start-page: 490 issue: 4 year: 2006 end-page: 494 article-title: Expression of CXCL13 by neoplastic cells in angioimmunoblastic T‐cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T‐cells publication-title: Am J Surg Pathol – volume: 28 start-page: 1287 issue: 12 year: 2004 end-page: 1292 article-title: Clinicopathological features and prognostic factors of Japanese patients with “peripheral T‐cell lymphoma, unspecified” diagnosed according to the WHO classification publication-title: Leuk Res – volume: 328 start-page: 1002 issue: 14 year: 1993 end-page: 1006 article-title: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non‐Hodgkin's lymphoma publication-title: N Engl J Med – volume: 59 start-page: 1187 issue: 6 year: 1987 end-page: 1191 article-title: Hypercalcemia and osteoclast proliferation in adult T‐cell leukemia publication-title: Cancer – volume: 89 start-page: 3909 issue: 11 year: 1997 end-page: 3918 article-title: A clinical evaluation of the International Lymphoma Study Group classification of non‐Hodgkin's lymphoma publication-title: Blood – volume: 71 start-page: 2335 issue: 7 year: 1993 end-page: 2341 article-title: Cyclosporine treatment of refractory T‐cell lymphomas publication-title: Cancer – volume: 15 start-page: 1091 issue: 7 year: 2004 end-page: 1096 article-title: Chromosomal abnormalities of 200 Chinese patients with non‐Hodgkin's lymphoma in Taiwan: with special reference to T‐cell lymphoma publication-title: Ann Oncol – volume: 11 start-page: 359 issue: 3 year: 2000 end-page: 361 article-title: Activity of interferon‐alpha in relapsed patients with diffuse large B‐cell and peripheral T‐cell non‐Hodgkin's lymphoma publication-title: Ann Oncol – volume: 104 year: 2004 article-title: Combination chemoimmunotherapy using Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (campath‐FCD) is an effective first‐line regimen in peripheral T‐cell lymphomas publication-title: Blood – volume: 120 start-page: 978 issue: 6 year: 2003 end-page: 985 article-title: Autologous stem cell transplant for relapsed and refractory peripheral T‐cell lymphoma: variable outcome according to pathological subtype publication-title: Br J Haematol – volume: 1 start-page: S51 issue: Suppl. 1 year: 2000 end-page: S55 article-title: Bexarotene and DAB(389)IL‐2 (denileukin diftitox, ONTAK) in treatment of cutaneous T‐cell lymphomas: algorithms publication-title: Clin Lymphoma – volume: 37 start-page: 439 issue: 5 year: 2006 end-page: 449 article-title: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe publication-title: Bone Marrow Transplant – volume: 87 start-page: 1045 issue: 3 year: 1996 end-page: 1055 article-title: Epstein‐Barr virus genome in non‐Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T‐cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO publication-title: Blood – volume: 10 start-page: 5494 issue: 16 year: 2004 end-page: 5500 article-title: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T‐cell and NK‐cell lymphomas with special reference to clinicopathological significance for peripheral T‐cell lymphoma, unspecified publication-title: Clin Cancer Res – volume: 15 start-page: 1131 issue: 3 year: 1997 end-page: 1137 article-title: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor‐risk aggressive non‐Hodgkin's lymphoma: updated results of the prospective study LN H87‐2. Groupe d'Etude des Lymphomes de l'Adulte publication-title: J Clin Oncol – volume: 117 start-page: 71 issue: 1 year: 2000 end-page: 79 article-title: Chromosome abnormalities in peripheral T‐cell lymphoma publication-title: Cancer Genet Cytogenet – volume: 108 start-page: 4163 issue: 13 year: 2006 end-page: 4169 article-title: Prognostic significance of Epstein‐Barr virus in nodal peripheral T‐cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study publication-title: Blood – start-page: 191 year: 2001 end-page: 194 – volume: 17 start-page: 275 issue: 2 year: 2006 end-page: 278 article-title: Assigning the phenotype of a natural regulatory T‐cell to the human T‐cell line, KARPAS‐299 publication-title: Int J Mol Med – volume: 83 start-page: 505 issue: 2 year: 1994 end-page: 511 article-title: Cytogenetic findings in peripheral T‐cell lymphomas as a basis for distinguishing low‐grade and high‐grade lymphomas publication-title: Blood – volume: 19 start-page: 1993 issue: 11 year: 2005 end-page: 1995 article-title: Complete remission in a patient with relapsed angioimmunoblastic T‐cell lymphoma following treatment with bevacizumab publication-title: Leukemia – volume: 103 start-page: 2474 issue: 7 year: 2004 end-page: 2479 article-title: Peripheral T‐cell lymphoma unspecified (PTCL‐U): a new prognostic model from a retrospective multicentric clinical study publication-title: Blood – volume: 104 start-page: 721a year: 2004 article-title: Phase I/II, open‐label, dose‐escalating study of MDX‐060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma publication-title: Blood – volume: 5 start-page: 304 issue: 4 year: 2004 end-page: 311 article-title: Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first‐line therapy in peripheral T‐cell lymphomas: first results of a prospective multicenter study publication-title: Hematol J – volume: 111 start-page: S46 issue: Suppl. 1 year: 1999 end-page: S55 article-title: Extranodal peripheral T‐cell and NK‐cell neoplasms publication-title: Am J Clin Pathol – volume: 9 start-page: 849 issue: 8 year: 1998 end-page: 855 article-title: Peripheral T‐cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification publication-title: Ann Oncol – volume: 93 start-page: 3913 issue: 11 year: 1999 end-page: 3921 article-title: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma publication-title: Blood – volume: 22 start-page: 591 year: 2003 article-title: Intensified induction therapy with etoposide (VP16) and high‐dose cytarabine (Ara‐C) in patients aged less than 60 years with peripheral T‐cell/NK lymphoma: Preliminary results of the phase II GELA study LNH98 T7 publication-title: Proc Am Soc Clin Oncol – volume: 76 start-page: 109 issue: 2 year: 2006 end-page: 118 article-title: Association of Epstein‐Barr virus with human immunodeficiency virus‐negative peripheral T‐cell lymphomas in Japan publication-title: Eur J Haematol – volume: 80 start-page: 587 issue: 3 year: 1992 end-page: 592 article-title: 2‐Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T‐cell lymphoma publication-title: Blood – volume: 96 start-page: 527 issue: 8 year: 2005 end-page: 533 article-title: Possible origin of adult T‐cell leukemia/lymphoma cells from human T lymphotropic virus type‐1‐infected regulatory T‐cells publication-title: Cancer Sci – volume: 941 start-page: 200 year: 2001 end-page: 205 article-title: Therapy of T‐cell lymphomas with pentostatin publication-title: Ann N Y Acad Sci – volume: 78 start-page: 15 issue: 1 year: 1994 end-page: 22 article-title: Recurrent chromosome abnormalities in peripheral T‐cell lymphomas publication-title: Cancer Genet Cytogenet – volume: 10 start-page: 1557 issue: 11 year: 1994 end-page: 1566 article-title: Molecular epidemiology of HTLV type I in Japan: evidence for two distinct ancestral lineages with a particular geographical distribution publication-title: AIDS Res Hum Retroviruses – volume: 7 start-page: 725 issue: 6 year: 1989 end-page: 731 article-title: Direct comparisons of peripheral T‐cell lymphoma with diffuse B‐cell lymphoma of comparable histological grades—should peripheral T‐cell lymphoma be considered separately? publication-title: J Clin Oncol – volume: 46 start-page: 179 issue: 3 year: 1994 end-page: 183 article-title: Differential expression of interleukin‐2 receptors (alpha and beta chain) in mature lymphoid neoplasms publication-title: Am J Hematol – volume: 13 start-page: 140 issue: 1 year: 2002 end-page: 149 article-title: Peripheral T‐cell lymphoma (excluding anaplastic large‐cell lymphoma): results from the Non‐Hodgkin's Lymphoma Classification Project publication-title: Ann Oncol – volume: 15 start-page: 618 issue: 4 year: 2004 end-page: 625 article-title: Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T‐cell lymphoma: a single institute survey in Taiwan publication-title: Ann Oncol – volume: 343 start-page: 37 issue: 1 year: 2000 end-page: 49 article-title: The immune system. First of two parts publication-title: N Engl J Med – volume: 24 start-page: 113 issue: 3 year: 2006 end-page: 119 article-title: Peripheral T‐cell lymphoma gene expression profiles publication-title: Hematol Oncol – volume: 16 start-page: v74 issue: Suppl. 5 year: 2005 article-title: Gene expression analysis of peripheral T‐cell lymphoma not otherwise specified reveals the existance of two subgroups related to different‐cellular counterparts publication-title: Ann Oncol – volume: 13 start-page: 82 issue: Suppl. 2 year: 2002 article-title: Early stage nasal NK/T‐cell lymphoma: preliminary result of intensifying treatment with concurrent chemo‐radiation and high dose chemotherapy publication-title: Annals of Oncology – volume: 54 start-page: 182 issue: 1 year: 2002 end-page: 190 article-title: Early stage nasal NK/T‐cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality publication-title: Int J Radiat Oncol Biol Phys – volume: 38 start-page: 75 issue: 1 year: 2002 end-page: 81 article-title: Clinical features of peripheral T‐cell lymphomas in 78 patients diagnosed according to the Revised European‐American lymphoma (REAL) classification publication-title: Eur J Cancer – year: 1992 – volume: 1006 start-page: 239 issue: 11 year: 2005 article-title: International Peripheral T‐Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines publication-title: Blood – volume: 126 start-page: 575 issue: 3 year: 2006 end-page: 583 article-title: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T‐cell lymphoma publication-title: J Invest Dermatol – volume: 210 start-page: 172 issue: 2 year: 2006 end-page: 180 article-title: Nodal peripheral T‐cell lymphomas correspond to distinct mature T‐cell populations publication-title: J Pathol – volume: 136 start-page: 439 issue: 3 year: 2007 end-page: 447 article-title: Phase II trial of denileukin diftitox for relapsed/refractory T‐cell non‐Hodgkin lymphoma publication-title: Br J Haematol – volume: 100 start-page: 1969 issue: 8 year: 1997 end-page: 1979 article-title: Upregulation of tumor necrosis factor‐alpha gene by Epstein‐Barr virus and activation of macrophages in Epstein‐Barr virus‐infected T‐cells in the pathogenesis of hemophagocytic syndrome publication-title: J Clin Invest – volume: 10 start-page: 4971 issue: 15 year: 2004 end-page: 4982 article-title: Expression profiling of T‐cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes publication-title: Clin Cancer Res – volume: 19 start-page: 3766 issue: 17 year: 2001 end-page: 3770 article-title: Impact of high‐dose chemotherapy on peripheral T‐cell lymphomas publication-title: J Clin Oncol – volume: 192 start-page: 1545 issue: 11 year: 2000 end-page: 1552 article-title: Follicular B helper T‐cells express CXC chemokine receptor 5, localize to B‐cell follicles, and support immunoglobulin production publication-title: J Exp Med – volume: 24 start-page: 2472 issue: 16 year: 2006 end-page: 2479 article-title: Marker expression in peripheral T‐cell lymphoma: a proposed clinical‐pathologic prognostic score publication-title: J Clin Oncol – volume: 106 year: 2005 article-title: Report of a phase II study of proteasome inhibitor Bortezomib (Velcade) in patients with relapsed or refractory T‐cell lymphoma publication-title: Blood – volume: 6 start-page: 6 issue: 1 year: 2005 end-page: 10 article-title: Advances in targeted therapeutics for T‐cell lymphomas publication-title: Monogr Lymphoma – volume: 26 start-page: 3699 issue: 25 year: 2007 end-page: 3703 article-title: Daclizumab (anti‐Tac, Zenapax) in the treatment of leukemia/lymphoma publication-title: Oncogene – volume: 103 start-page: 4636 issue: 12 year: 2004 end-page: 4643 article-title: T‐cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance publication-title: Blood – volume: 44 start-page: 241 issue: 2 year: 2003 end-page: 249 article-title: Peripheral T‐cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification publication-title: Leuk Lymphoma – volume: 40 start-page: 995 issue: 9 year: 1987 end-page: 1015 article-title: Histopathology and immunohistochemistry of peripheral T‐cell lymphomas: a proposal for their classification publication-title: J Clin Pathol – volume: 15 start-page: 1467 issue: 10 year: 2004 end-page: 1475 article-title: Characterization of peripheral T‐cell lymphomas in a single North American institution by the WHO classification publication-title: Ann Oncol – volume: 63 start-page: 158 issue: 1 year: 1989 end-page: 163 article-title: Peripheral T‐cell lymphoma publication-title: Cancer – volume: 19 start-page: 376 issue: 2 year: 2001 end-page: 388 article-title: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T‐cell lymphoma publication-title: J Clin Oncol – volume: 9 start-page: 1426 issue: 8 year: 1991 end-page: 1431 article-title: Similar outcome of treatment of B‐cell and T‐cell diffuse large‐cell lymphomas: the Stanford experience publication-title: J Clin Oncol – volume: 105 start-page: 1640 issue: 4 year: 2005 end-page: 1647 article-title: Cutaneous T‐cell lymphoma: malignant proliferation of T‐regulatory cells publication-title: Blood – volume: 343 start-page: 108 issue: 2 year: 2000 end-page: 117 article-title: The immune system. Second of two parts publication-title: N Engl J Med – volume: 80 start-page: 1804 issue: 7 year: 1992 end-page: 1812 article-title: Heterogeneous Epstein‐Barr virus infection patterns in peripheral T‐cell lymphoma of angioimmunoblastic lymphadenopathy type publication-title: Blood – volume: 100 start-page: 342 issue: 2 year: 2004 end-page: 349 article-title: Phase II study of pentostatin in advanced T‐cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series publication-title: Cancer – volume: 131 start-page: 223 issue: 2 year: 2005 end-page: 230 article-title: Allogeneic haematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma publication-title: Br J Haematol – volume: 2 start-page: 159 issue: 8551 year: 1987 article-title: Risk of adult T‐cell leukaemia/lymphoma in HTLV‐I carriers publication-title: Lancet – volume: 18 start-page: 2603 issue: 13 year: 2000 end-page: 2606 article-title: Gemcitabine treatment in pretreated cutaneous T‐cell lymphoma: experience in 44 patients publication-title: J Clin Oncol – volume: 24 start-page: 175 issue: 4 year: 2006 end-page: 180 article-title: ‘Normal counterparts’ of nodal peripheral T‐cell lymphoma publication-title: Hematol Oncol – volume: 92 start-page: 76 issue: 1 year: 1998 end-page: 82 article-title: Prognostic significance of T‐cell phenotype in aggressive non‐Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) publication-title: Blood – volume: 5 start-page: 853 issue: 11 year: 2005 end-page: 865 article-title: Follicular B helper T‐cells in antibody responses and autoimmunity publication-title: Nat Rev Immunol – volume: 113 start-page: 185 issue: 1 year: 2001 end-page: 187 article-title: Treatment of refractory T‐cell malignancies using gemcitabine publication-title: Br J Haematol – volume: 42 start-page: 7 issue: 1 year: 1988 end-page: 712 article-title: Geographic distribution of HTLV‐I and identification of a new high‐risk population publication-title: Int J Cancer – volume: 12 start-page: 2588 issue: 12 year: 1994 end-page: 2593 article-title: The role of pentostatin in the treatment of T‐cell malignancies: analysis of response rate in 145 patients according to disease subtype publication-title: J Clin Oncol – volume: 129 start-page: 366 issue: 3 year: 2005 end-page: 372 article-title: The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas publication-title: Br J Haematol – volume: 151 start-page: 103 issue: 1 year: 2007 end-page: 107 article-title: Peripheral T‐cell lymphoma, unspecified ‐ the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub – volume: 53 start-page: 163 issue: 2 year: 1996 end-page: 168 article-title: Pentostatin (2′‐deoxycoformycin, dCF) in patients with low‐grade (B‐T‐cell) and intermediate‐ and high‐grade (T‐cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group publication-title: Oncology – volume: 103 start-page: 82920 year: 2004 end-page: 82924 article-title: A pilot study of alemtuzumab (anti‐CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy‐refractory peripheral T‐cell lymphomas publication-title: Blood – volume: 17 start-page: 638 issue: 6 year: 2005 end-page: 642 article-title: How do CD4+ CD25+ regulatory T‐cells control autoimmunity? publication-title: Curr Opin Immunol – volume: 96 start-page: 685 issue: 2 year: 2000 end-page: 690 article-title: Expression pattern of T‐cell‐associated chemokine receptors and their chemokines correlates with specific subtypes of T‐cell non‐Hodgkin lymphoma publication-title: Blood – volume: 173 start-page: 6169 issue: 10 year: 2004 end-page: 6178 article-title: Follicular dendritic cell regulation of CXCR4‐mediated germinal center CD4 T‐cell migration publication-title: J Immunol – volume: 82 start-page: 171 issue: 2 year: 1997 end-page: 177 article-title: Retrospective analysis of 23 cases with peripheral T‐cell lymphoma, unspecified: clinical characteristics and outcome publication-title: Haematologica – volume: 25 start-page: 1560 issue: 10 year: 2006 end-page: 1570 article-title: Gene expression profiling identifies molecular subgroups among nodal peripheral T‐cell lymphomas publication-title: Oncogene – volume: 83 start-page: 1612 issue: 6 year: 1994 end-page: 1618 article-title: Presence of Epstein‐Barr virus in extranodal T‐cell lymphomas: differences in relation to site publication-title: Blood – volume: 84 start-page: 1512 issue: 11 year: 2004 end-page: 1519 article-title: Vascular endothelial growth factor‐A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T‐cell lymphoma and related to lymphoma progression publication-title: Lab Invest – volume: 81 start-page: 646 issue: 11 year: 2002 end-page: 650 article-title: Treatment of peripheral T‐cell lymphomas (PTCL) with high‐dose chemotherapy and autologous or allogeneic hematopoietic transplantation publication-title: Ann Hematol – start-page: 405 year: 2004 end-page: 426 – volume: 15 start-page: 1447 issue: 10 year: 2004 end-page: 1449 article-title: Towards understanding the peripheral T‐cell lymphomas publication-title: Ann Oncol – volume: 87 start-page: 1207 issue: 4 year: 1996 end-page: 1210 article-title: Classification of natural killer (NK) cell and NK‐like T‐cell malignancies publication-title: Blood – volume: 12 start-page: 341 issue: 5 year: 1988 end-page: 350 article-title: Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma) publication-title: Am J Surg Pathol – volume: 43 start-page: 133 issue: 1 year: 2002 end-page: 137 article-title: Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports publication-title: Leuk Lymphoma – volume: 47 start-page: 998 issue: 6 year: 2006 end-page: 1005 article-title: Rituximab, bevacizumab and CHOP (RA‐CHOP) in untreated diffuse large B‐cell lymphoma: safety, biomarker and pharmacokinetic analysis publication-title: Leuk Lymphoma – volume: 89 start-page: 4514 issue: 12 year: 1997 end-page: 4520 article-title: Evaluation of the revised European‐American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non‐Hodgkin's lymphoma publication-title: Blood – volume: 126 start-page: 81 issue: 1 year: 2004 end-page: 84 article-title: Expression of FoxP3, a key molecule in CD4CD25 regulatory T‐cells, in adult T‐cell leukaemia/lymphoma cells publication-title: Br J Haematol – start-page: 30 year: 2002 end-page: 43 – volume: 104 start-page: 682a year: 2004 article-title: CALGB 59901:Results of a Phase II Study of 506U78 in CTCL and PTCL publication-title: Blood – volume: 96 start-page: 3681 issue: 12 year: 2000 end-page: 3695 article-title: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features publication-title: Blood – volume: 103 start-page: 236 issue: 1 year: 2004 end-page: 241 article-title: Th1, Th2, and activated T‐cell marker and clinical prognosis in peripheral T‐cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL publication-title: Blood – volume: 72 start-page: 436 issue: 2 year: 1988 end-page: 441 article-title: The prognostic significance of the immunotype in diffuse large‐cell lymphoma: a comparative study of the T‐cell and B‐cell phenotype publication-title: Blood – volume: 1 start-page: 45 issue: 1 year: 1990 end-page: 50 article-title: Peripheral T‐cell lymphomas have a worse prognosis than B‐cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH‐84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives) publication-title: Ann Oncol – volume: 98 start-page: 2865 issue: 9 year: 2001 end-page: 2868 article-title: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T‐cell lymphoma: a case report publication-title: Blood – volume: 17 start-page: 567 issue: 6 year: 1986 end-page: 574 article-title: The phenotypic diversity of peripheral T‐cell lymphomas: the Southeastern Cancer Study Group experience publication-title: Hum Pathol – volume: 93 start-page: 2697 issue: 8 year: 1999 end-page: 2706 article-title: ALK+ lymphoma: clinico‐pathological findings and outcome publication-title: Blood – volume: 106 start-page: 937a year: 2005 article-title: HuMax‐CD4 (zanolimumab), a fully human monoclonal antibody: early results of an ongoing clinical trial in CD4+ peripheral T‐cell lymphoma of non‐cutaneous typ publication-title: Blood – volume: 7 start-page: 1301 issue: 10 year: 2006 end-page: 1311 article-title: Immunotoxins in the treatment of hematologic malignancies publication-title: Curr Drug Targets – year: 2006 – volume: 18 start-page: 349 issue: 3 year: 2006 end-page: 356 article-title: Expanding the effector CD4 T‐cell repertoire: the Th17 lineage publication-title: Curr Opin Immunol – volume: 104 start-page: 721a year: 2004 end-page: 722a article-title: SGN‐30 (Anti‐CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma publication-title: Blood – volume: 24 start-page: 121 issue: 1–2 year: 1996 end-page: 129 article-title: Peripheral T‐cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high‐grade B‐cell lymphomas publication-title: Leuk Lymphoma – volume: 104 start-page: 1952 issue: 7 year: 2004 end-page: 1960 article-title: Unique gene expression program of human germinal center T helper cells publication-title: Blood – volume: 88 start-page: 1372 issue: 12 year: 2003 end-page: 1377 article-title: High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T‐cell lymphoma not achieving complete response after induction chemotherapy. The GEL‐TAMO experience publication-title: Haematologica – volume: 8 start-page: 583 issue: 6 year: 1997 end-page: 592 article-title: Peripheral T‐cell lymphomas. Clinico‐pathologic study of 168 cases diagnosed according to the R.E.A.L. classification publication-title: Ann Oncol – volume: 84 start-page: 1361 issue: 5 year: 1994 end-page: 1392 article-title: A revised European‐ American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group publication-title: Blood – volume: 15 start-page: 2296 issue: 6 year: 1997 end-page: 2301 article-title: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T‐cell lymphoma publication-title: J Clin Oncol – volume: 19 start-page: 2254 issue: 12 year: 2005 end-page: 2263 article-title: Differential expression of NF‐kappaB pathway genes among peripheral T‐cell lymphomas publication-title: Leukemia – volume: 104 start-page: 2437 issue: 11 year: 2005 end-page: 2441 article-title: Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma: phase II study of 32 patients publication-title: Cancer – volume: 17 start-page: 3835 issue: 12 year: 1999 end-page: 3849 article-title: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐airlie house, Virginia, November 1997 publication-title: J Clin Oncol – volume: 118 start-page: 316 issue: 2 year: 1985 end-page: 324 article-title: Morphologic and immunologic characterization of 50 peripheral T‐cell lymphomas publication-title: Am J Pathol – volume: 102 start-page: 4284 issue: 13 year: 2003 end-page: 4289 article-title: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor‐prognosis aggressive non‐Hodgkin lymphoma publication-title: Blood – ident: e_1_2_1_52_2 doi: 10.1007/978-3-642-97187-7 – ident: e_1_2_1_96_2 doi: 10.1182/blood-2003-10-3389 – volume: 92 start-page: 76 issue: 1 year: 1998 ident: e_1_2_1_63_2 article-title: Prognostic significance of T‐cell phenotype in aggressive non‐Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA) publication-title: Blood contributor: fullname: Gisselbrecht C – volume: 104 start-page: 682a year: 2004 ident: e_1_2_1_95_2 article-title: CALGB 59901:Results of a Phase II Study of 506U78 in CTCL and PTCL publication-title: Blood doi: 10.1182/blood.V104.11.2486.2486 contributor: fullname: Czuczman M – ident: e_1_2_1_121_2 doi: 10.1046/j.1365-2141.2003.04203.x – volume: 96 start-page: 685 issue: 2 year: 2000 ident: e_1_2_1_33_2 article-title: Expression pattern of T‐cell‐associated chemokine receptors and their chemokines correlates with specific subtypes of T‐cell non‐Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood.V96.2.685.014k26_685_690 contributor: fullname: Jones D – ident: e_1_2_1_124_2 doi: 10.1007/s00277-002-0556-2 – ident: e_1_2_1_29_2 doi: 10.1038/modpathol.3800625 – ident: e_1_2_1_3_2 doi: 10.1182/blood.V89.11.3909 – ident: e_1_2_1_105_2 doi: 10.1200/JCO.2001.19.2.376 – volume: 80 start-page: 1804 issue: 7 year: 1992 ident: e_1_2_1_11_2 article-title: Heterogeneous Epstein‐Barr virus infection patterns in peripheral T‐cell lymphoma of angioimmunoblastic lymphadenopathy type publication-title: Blood doi: 10.1182/blood.V80.7.1804.1804 contributor: fullname: Anagnostopoulos I – ident: e_1_2_1_54_2 doi: 10.1016/S0046-8177(86)80128-9 – ident: e_1_2_1_24_2 doi: 10.1182/blood-2004-03-1206 – ident: e_1_2_1_71_2 doi: 10.1182/blood.V72.2.436.436 – ident: e_1_2_1_128_2 doi: 10.1002/1097-0142(19930401)71:7<2335::AID-CNCR2820710727>3.0.CO;2-D – volume: 84 start-page: 1361 issue: 5 year: 1994 ident: e_1_2_1_68_2 article-title: A revised European‐ American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group publication-title: Blood doi: 10.1182/blood.V84.5.1361.1361 contributor: fullname: Harris NL – ident: e_1_2_1_7_2 doi: 10.1002/ijc.2910420103 – ident: e_1_2_1_62_2 doi: 10.1038/sj.thj.6200359 – start-page: 405 volume-title: Non‐Hodgkin's Lymphomas year: 2004 ident: e_1_2_1_17_2 contributor: fullname: Armitage JO – ident: e_1_2_1_23_2 doi: 10.1038/nri1714 – volume: 13 start-page: 82 issue: 2 year: 2002 ident: e_1_2_1_82_2 article-title: Early stage nasal NK/T‐cell lymphoma: preliminary result of intensifying treatment with concurrent chemo‐radiation and high dose chemotherapy publication-title: Annals of Oncology contributor: fullname: Cheung MM – volume: 6 start-page: 6 issue: 1 year: 2005 ident: e_1_2_1_98_2 article-title: Advances in targeted therapeutics for T‐cell lymphomas publication-title: Monogr Lymphoma contributor: fullname: Dang N – ident: e_1_2_1_5_2 doi: 10.1093/annonc/mdf033 – volume: 87 start-page: 1045 issue: 3 year: 1996 ident: e_1_2_1_76_2 article-title: Epstein‐Barr virus genome in non‐Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T‐cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO publication-title: Blood doi: 10.1182/blood.V87.3.1045.bloodjournal8731045 contributor: fullname: d'Amore F – volume: 1 start-page: 45 issue: 1 year: 1990 ident: e_1_2_1_64_2 article-title: Peripheral T‐cell lymphomas have a worse prognosis than B‐cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH‐84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives) publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a057673 contributor: fullname: Coiffier B – ident: e_1_2_1_123_2 doi: 10.1111/j.1365-2141.2005.05755.x – volume: 1006 start-page: 239 issue: 11 year: 2005 ident: e_1_2_1_6_2 article-title: International Peripheral T‐Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines publication-title: Blood contributor: fullname: Vose JM – ident: e_1_2_1_22_2 doi: 10.4049/jimmunol.173.10.6169 – volume: 16 start-page: v131 issue: 5 year: 2005 ident: e_1_2_1_86_2 article-title: ESHAP chemotherapy regimen and 13‐cis‐retinoic acid in elderly patients with untreated poor‐prognosis peripheral T‐cell lymphoma: a GELA phase II trial of feasability and efficacy publication-title: Annals of Oncology contributor: fullname: Bouabdallah R – ident: e_1_2_1_18_2 doi: 10.1016/j.coi.2006.03.017 – volume: 106 start-page: 937a year: 2005 ident: e_1_2_1_99_2 article-title: HuMax‐CD4 (zanolimumab), a fully human monoclonal antibody: early results of an ongoing clinical trial in CD4+ peripheral T‐cell lymphoma of non‐cutaneous typ publication-title: Blood contributor: fullname: d'Amore F – volume: 106 year: 2005 ident: e_1_2_1_115_2 article-title: Report of a phase II study of proteasome inhibitor Bortezomib (Velcade) in patients with relapsed or refractory T‐cell lymphoma publication-title: Blood doi: 10.1182/blood.V106.11.4764.4764 contributor: fullname: Zinzani PL – ident: e_1_2_1_50_2 doi: 10.1136/jcp.40.9.995 – ident: e_1_2_1_78_2 doi: 10.1200/JCO.2005.03.6327 – ident: e_1_2_1_104_2 doi: 10.1038/sj.jid.5700122 – ident: e_1_2_1_130_2 doi: 10.1016/S0959-8049(01)00344-6 – ident: e_1_2_1_91_2 doi: 10.1159/000227554 – volume: 80 start-page: 587 issue: 3 year: 1992 ident: e_1_2_1_129_2 article-title: 2‐Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T‐cell lymphoma publication-title: Blood doi: 10.1182/blood.V80.3.587.587 contributor: fullname: Saven A – volume: 83 start-page: 505 issue: 2 year: 1994 ident: e_1_2_1_40_2 article-title: Cytogenetic findings in peripheral T‐cell lymphomas as a basis for distinguishing low‐grade and high‐grade lymphomas publication-title: Blood doi: 10.1182/blood.V83.2.505.505 contributor: fullname: Schlegelberger B – start-page: 30 volume-title: Text atlas of lymphomas (revised edition) year: 2002 ident: e_1_2_1_55_2 contributor: fullname: Armitage JO – ident: e_1_2_1_67_2 doi: 10.1200/JCO.1999.17.12.3835 – ident: e_1_2_1_46_2 doi: 10.1038/sj.leu.2403960 – ident: e_1_2_1_41_2 doi: 10.1016/S0165-4608(99)00151-X – ident: e_1_2_1_42_2 doi: 10.1093/annonc/mdh263 – ident: e_1_2_1_51_2 doi: 10.1097/00000478-198805000-00002 – ident: e_1_2_1_77_2 doi: 10.1182/blood-2006-04-017632 – ident: e_1_2_1_13_2 doi: 10.1002/path.2046 – ident: e_1_2_1_31_2 doi: 10.1182/blood-2002-05-1352 – volume: 111 start-page: S46 issue: 1 year: 1999 ident: e_1_2_1_37_2 article-title: Extranodal peripheral T‐cell and NK‐cell neoplasms publication-title: Am J Clin Pathol contributor: fullname: Jaffe ES – ident: e_1_2_1_35_2 doi: 10.1172/JCI119728 – ident: e_1_2_1_70_2 doi: 10.1182/blood.V93.11.3913 – ident: e_1_2_1_89_2 doi: 10.1200/JCO.1994.12.12.2588 – start-page: 191 volume-title: World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues year: 2001 ident: e_1_2_1_2_2 contributor: fullname: Jaffe ES – ident: e_1_2_1_21_2 doi: 10.1084/jem.192.11.1545 – ident: e_1_2_1_107_2 doi: 10.3816/CLM.2000.s.010 – ident: e_1_2_1_127_2 doi: 10.1023/A:1008384506227 – ident: e_1_2_1_88_2 doi: 10.1002/cncr.11899 – ident: e_1_2_1_80_2 doi: 10.1016/S0360-3016(02)02916-4 – volume: 17 start-page: 275 issue: 2 year: 2006 ident: e_1_2_1_26_2 article-title: Assigning the phenotype of a natural regulatory T‐cell to the human T‐cell line, KARPAS‐299 publication-title: Int J Mol Med contributor: fullname: Wolke C – volume: 83 start-page: 1612 issue: 6 year: 1994 ident: e_1_2_1_12_2 article-title: Presence of Epstein‐Barr virus in extranodal T‐cell lymphomas: differences in relation to site publication-title: Blood doi: 10.1182/blood.V83.6.1612.1612 contributor: fullname: de Bruin PC – ident: e_1_2_1_32_2 doi: 10.1158/1078-0432.CCR-04-0371 – ident: e_1_2_1_106_2 doi: 10.1111/j.1365-2141.2006.06457.x – ident: e_1_2_1_47_2 doi: 10.1038/sj.onc.1209178 – volume: 118 start-page: 316 issue: 2 year: 1985 ident: e_1_2_1_53_2 article-title: Morphologic and immunologic characterization of 50 peripheral T‐cell lymphomas publication-title: Am J Pathol contributor: fullname: Weiss LM – ident: e_1_2_1_117_2 doi: 10.1182/blood-2003-09-3068 – ident: e_1_2_1_38_2 doi: 10.1182/blood.V96.12.3681 – ident: e_1_2_1_20_2 doi: 10.1016/j.coi.2005.09.002 – ident: e_1_2_1_44_2 doi: 10.1002/hon.781 – ident: e_1_2_1_10_2 doi: 10.1111/j.0902-4441.2005.00575.x – ident: e_1_2_1_30_2 doi: 10.1097/00000478-200604000-00009 – ident: e_1_2_1_15_2 doi: 10.1056/NEJM200007133430207 – ident: e_1_2_1_4_2 doi: 10.1093/annonc/mdh409 – ident: e_1_2_1_25_2 doi: 10.1182/blood-2004-06-2181 – ident: e_1_2_1_84_2 doi: 10.3816/CLM.2003.n.027 – volume: 19 start-page: 3766 issue: 17 year: 2001 ident: e_1_2_1_118_2 article-title: Impact of high‐dose chemotherapy on peripheral T‐cell lymphomas publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.17.3766 contributor: fullname: Rodriguez J – ident: e_1_2_1_56_2 doi: 10.1023/A:1008200307625 – volume: 9 start-page: 1426 issue: 8 year: 1991 ident: e_1_2_1_73_2 article-title: Similar outcome of treatment of B‐cell and T‐cell diffuse large‐cell lymphomas: the Stanford experience publication-title: J Clin Oncol doi: 10.1200/JCO.1991.9.8.1426 contributor: fullname: Kwak LW – ident: e_1_2_1_16_2 doi: 10.1056/NEJM200007063430107 – volume: 18 start-page: 2603 issue: 13 year: 2000 ident: e_1_2_1_94_2 article-title: Gemcitabine treatment in pretreated cutaneous T‐cell lymphoma: experience in 44 patients publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.13.2603 contributor: fullname: Zinzani PL – ident: e_1_2_1_93_2 doi: 10.1002/cncr.21449 – ident: e_1_2_1_90_2 doi: 10.1111/j.1749-6632.2001.tb03724.x – ident: e_1_2_1_9_2 doi: 10.1089/aid.1994.10.1557 – ident: e_1_2_1_60_2 doi: 10.1093/annonc/mdh392 – ident: e_1_2_1_111_2 doi: 10.1080/10428190210190 – ident: e_1_2_1_39_2 doi: 10.1016/0165-4608(94)90040-X – ident: e_1_2_1_131_2 doi: 10.5507/bp.2007.019 – start-page: 227 volume-title: World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues year: 2001 ident: e_1_2_1_49_2 contributor: fullname: Ralfkiaer E – ident: e_1_2_1_125_2 doi: 10.1200/JCO.2004.12.050 – ident: e_1_2_1_65_2 doi: 10.1200/JCO.1997.15.6.2296 – volume: 104 start-page: 721a year: 2004 ident: e_1_2_1_102_2 article-title: Phase I/II, open‐label, dose‐escalating study of MDX‐060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma publication-title: Blood doi: 10.1182/blood.V104.11.2636.2636 contributor: fullname: Ansell S – volume: 7 start-page: 725 issue: 6 year: 1989 ident: e_1_2_1_72_2 article-title: Direct comparisons of peripheral T‐cell lymphoma with diffuse B‐cell lymphoma of comparable histological grades—should peripheral T‐cell lymphoma be considered separately? publication-title: J Clin Oncol doi: 10.1200/JCO.1989.7.6.725 contributor: fullname: Cheng AL – ident: e_1_2_1_83_2 doi: 10.1182/blood-2003-02-0542 – ident: e_1_2_1_19_2 doi: 10.1038/nature04753 – ident: e_1_2_1_85_2 doi: 10.3109/10428199609045720 – ident: e_1_2_1_8_2 doi: 10.1016/S0140-6736(87)92359-2 – ident: e_1_2_1_45_2 doi: 10.1158/1078-0432.CCR-04-0269 – ident: e_1_2_1_61_2 doi: 10.1182/blood-2003-09-3080 – volume: 104 year: 2004 ident: e_1_2_1_97_2 article-title: Combination chemoimmunotherapy using Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (campath‐FCD) is an effective first‐line regimen in peripheral T‐cell lymphomas publication-title: Blood doi: 10.1182/blood.V104.11.2640.2640 contributor: fullname: Weidmann E – ident: e_1_2_1_100_2 doi: 10.1385/MO:22:2:191 – ident: e_1_2_1_112_2 doi: 10.1038/sj.leu.2403936 – volume: 93 start-page: 2697 issue: 8 year: 1999 ident: e_1_2_1_69_2 article-title: ALK+ lymphoma: clinico‐pathological findings and outcome publication-title: Blood contributor: fullname: Falini B – ident: e_1_2_1_92_2 doi: 10.1046/j.1365-2141.2001.02743.x – volume: 104 start-page: 721a year: 2004 ident: e_1_2_1_101_2 article-title: SGN‐30 (Anti‐CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma publication-title: Blood doi: 10.1182/blood.V104.11.2637.2637 contributor: fullname: Forero‐Torres A – volume: 88 start-page: 1372 issue: 12 year: 2003 ident: e_1_2_1_122_2 article-title: High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T‐cell lymphoma not achieving complete response after induction chemotherapy. The GEL‐TAMO experience publication-title: Haematologica contributor: fullname: Rodriguez J – ident: e_1_2_1_114_2 – ident: e_1_2_1_28_2 doi: 10.1111/j.1349-7006.2005.00080.x – ident: e_1_2_1_75_2 doi: 10.1111/j.1365-2141.2005.05478.x – ident: e_1_2_1_108_2 doi: 10.2174/138945006778559139 – volume: 89 start-page: 4514 issue: 12 year: 1997 ident: e_1_2_1_66_2 article-title: Evaluation of the revised European‐American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non‐Hodgkin's lymphoma publication-title: Blood doi: 10.1182/blood.V89.12.4514 contributor: fullname: Melnyk A – ident: e_1_2_1_110_2 doi: 10.1038/labinvest.3700145 – ident: e_1_2_1_116_2 doi: 10.1182/blood.V98.9.2865 – ident: e_1_2_1_43_2 doi: 10.1016/S0002-9440(10)63742-X – ident: e_1_2_1_109_2 doi: 10.1038/sj.onc.1210368 – ident: e_1_2_1_34_2 doi: 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8 – ident: e_1_2_1_58_2 doi: 10.1080/1042819021000030054 – ident: e_1_2_1_57_2 doi: 10.1023/A:1008418727472 – ident: e_1_2_1_81_2 doi: 10.1093/annonc/mdh143 – ident: e_1_2_1_36_2 doi: 10.1182/blood.V87.4.1207.bloodjournal8741207 – ident: e_1_2_1_113_2 doi: 10.1080/10428190600563821 – ident: e_1_2_1_27_2 doi: 10.1111/j.1365-2141.2004.04999.x – ident: e_1_2_1_74_2 doi: 10.1002/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO;2-B – ident: e_1_2_1_126_2 doi: 10.1038/sj.bmt.1705265 – volume: 16 start-page: v74 issue: 5 year: 2005 ident: e_1_2_1_48_2 article-title: Gene expression analysis of peripheral T‐cell lymphoma not otherwise specified reveals the existance of two subgroups related to different‐cellular counterparts publication-title: Ann Oncol contributor: fullname: Piccaluga PP – ident: e_1_2_1_59_2 doi: 10.1016/j.leukres.2004.04.016 – ident: e_1_2_1_120_2 doi: 10.1200/JCO.1997.15.3.1131 – ident: e_1_2_1_14_2 doi: 10.1002/hon.786 – volume: 82 start-page: 171 issue: 2 year: 1997 ident: e_1_2_1_119_2 article-title: Retrospective analysis of 23 cases with peripheral T‐cell lymphoma, unspecified: clinical characteristics and outcome publication-title: Haematologica contributor: fullname: Zaja F – volume: 22 start-page: 591 year: 2003 ident: e_1_2_1_87_2 article-title: Intensified induction therapy with etoposide (VP16) and high‐dose cytarabine (Ara‐C) in patients aged less than 60 years with peripheral T‐cell/NK lymphoma: Preliminary results of the phase II GELA study LNH98 T7 publication-title: Proc Am Soc Clin Oncol contributor: fullname: Delmer A – ident: e_1_2_1_103_2 doi: 10.1002/ajh.2830460304 – ident: e_1_2_1_79_2 doi: 10.1056/NEJM199304083281404
SSID	ssj0009908
Score	2.0294168
SecondaryResourceType	review_article
Snippet	Peripheral T‐cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T‐cells, and constitute less than 15%... Peripheral T-cell lymphomas (PTCL) comprises a heterogeneous group of haematological tumours, which originate from mature T-cells, and constitute less than 15%...
SourceID	crossref pubmed wiley istex
SourceType	Aggregation Database Index Database Publisher
StartPage	8
SubjectTerms	Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Gene Expression Profiling Hematopoietic Stem Cell Transplantation Humans Immunophenotyping Immunotoxins - therapeutic use Lymphoma, T-Cell, Peripheral - genetics Lymphoma, T-Cell, Peripheral - immunology Lymphoma, T-Cell, Peripheral - therapy non-Hodgkin lymphoma peripheral T-cell lymphoma peripheral T‐cell lymphoma, unspecified Prognosis Proteasome Inhibitors unspecified
Title	Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review
URI	https://api.istex.fr/ark:/67375/WNG-J5TRWK1D-W/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhon.836 https://www.ncbi.nlm.nih.gov/pubmed/18050364
Volume	26
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA86QXzx-6N-kYchCpa1SZsmvonbHIpz6mS-lSZtcDg62Qfqm3-Cf6N_iUlau_kgCD61cE0b7i69u-TudwCUGWVOTLFru34UqwAFxzbnnrojDvc9yfzYgPo07oLmA63WNExO0eorw4coNtz0yjD_a73AIz6sTEBDH5WUKNZg2ypGMMUbuDWB22WmF50-VrOVVUJZuaweWcnH_bBDc5qlr1NGaNpRNZamvvSPOS6Dxdy9hKeZPqyAmSRdBfNX-QH6GrhpKY0zSAI92P58_9D79rD3pkSq84SO4TjVpZddqRxTeNgfwLQ_gqZG66U7TGBBOzqBEcyqXtbBfb3WPmvYeVcFW2AfExtjVwjBOXEkkr5LHBQlklIcUR3aISJJwgjyKIpJwBwpA0UmRCAhmMSJ4-ENUEr7abIFoHImSOwKSTRGjmCC8cjnnoiZKxzEJbMA_OZx-JyBZ4QZTDIKFWtCxRoLHBjeF_Ro8KRzzQI_7DTPwwu_fdu5dKthxwKbmXAmb6Iay4Z4FigbGfz2ibBx3VSX7b89tgMWspQQnWa2C0qjwTjZA7PDeLxvVOwLVeDS5A
link.rule.ids	315,782,786,1408,27933,27934,46064,46488
linkProvider	Wiley-Blackwell
linkToHtml	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwEB2xSMCFfSmrDxUCiYjEThybG2Ir0JYCReVmJU4sEChFhQq48Ql8I1-C7XTjgITEKZEcJ9bMODMez3sGKHLG3YQRz_GCKNELFJI4cezrO-rGga94kFhSn9J1WL1lh0eGJmevi4XJ-SF6CTczM-z_2kxwk5De7bOG3mk1MUKHYdSn2gwNfIPU-oS73J5GZzbWHO2XcA6YNV13Ox1_eKJRI9S3ATc0GKpaX3M89Z9RTsNkJ8JE-7lJzMBQms3CWKWzhz4HlzVtdJZM4BHVvz4-TeoePb5rrZpSoR3Uzgz68l7p2BRtNVsoa74gC9N6vX9OUa9tew9FKAe-zMPN8VH9oOR0DlZwJAkIdQjxpJRxTF2FVeBRF0epYoxEzKzuMFU05RT7DCc05K5SoW6mVGIpuSKp65MFGMmaWboESMcTNPGkooYmR3LJ4yiIfZlwT7o4VrwAqCtk8ZTzZ4icKRkLLRqhRVOATSv8XnvUejDlZmEgGtUTcRbUrxrn3qFoFGAx107_TczQ2VC_AEWrhN8-IUoXVX1Z_ttjGzBeqlfKonxaPV-BibxCxFSdrcLIS6udrsHwc9Jet_b2DbMu1ww
linkToPdf	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLZ4SIgL78d45oAQSFS0SZsl3BBjjNcYMDRuUZs0AjF102ACbvwEfiO_hCQdGxyQkDg1kpu0sp3YSezPABuccV8xEnhBFCuzQSHKS5LQtKifRKHmkXKgPpXrYvWWlQ4tTE6_1FeOD9E_cLMzw63XdoK3ld4dgIbeGSkxQodh1IxLLWw-IbUB3i53xejsvZpnzBLO82Vt191exx-GaNTy9OWbFfruqTpTU578x09OwUTPv0T7uUJMw1CazcDYee8GfRYua0blHJRAE9U_3t7twT1qvhqZ2kChHdTNbO7lvTaeKdpqdVDWekIuSev5_jFFfdr2HopRnvYyBzflw_pBxeuVVfAkiQj1CAmklElCfY11FFAfx6lmjMTM7u0w1TTlFIcMK1rkvtZFQ6ZUYim5JqkfknkYyVpZugjIeBNUBVJTC5IjueRJHCWhVDyQPk40LwD64rFo5-gZIsdJxsKwRhjWFGDT8b5PjzsPNtisGIlG9UicRPWrxmlQEo0CLOTCGYzELJgNDQuw4WTw2ydE5aJqHkt_e20dxmqlsjg7rp4uw3geHmJDzlZg5KnTTVdh-FF115y2fQI8QtWy
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Peripheral+T%E2%80%90cell+lymphomas%2C+unspecified+%28or+not+otherwise+specified%29%3A+a+review&rft.jtitle=Hematological+oncology&rft.au=Rodriguez%E2%80%90Abreu%2C+Delvys&rft.au=Filho%2C+Volmar+Belisario&rft.au=Zucca%2C+Emanuele&rft.date=2008-03-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0278-0232&rft.eissn=1099-1069&rft.volume=26&rft.issue=1&rft.spage=8&rft.epage=20&rft_id=info:doi/10.1002%2Fhon.836&rft.externalDBID=10.1002%252Fhon.836&rft.externalDocID=HON836
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0278-0232&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0278-0232&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0278-0232&client=summon